FDA grants accelerated approval to new treatment for advanced ovarian cancer
- Details
- Category: FDA
The U.S. Food and Drug Administration has granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test.
FDA research to help speed development of Zika virus vaccines and therapeutics
- Details
- Category: FDA
A new mouse model developed by scientists at the U.S. Food and Drug Administration may help in exploring the potential activity of Zika virus vaccines and therapeutics. Published today in PLoS Pathogens, is the description of a neonatal mouse model that provides a platform for potentially improving and expediting studies to understand the causes and effects (pathology) of the Zika virus.
FDA awards 21 grants to stimulate product development for rare diseases
- Details
- Category: FDA
The U.S. Food and Drug Administration today announced that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry with research spanning domestic and international clinical sites.
FDA launches #NaloxoneApp competition to spur innovative technologies to help reduce opioid overdose deaths
- Details
- Category: FDA
The U.S. Food and Drug Administration has announced the 2016 Naloxone App Competition, a public contest focused on developing innovative technologies to combat the rising epidemic of opioid overdose. The FDA, with support from the National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA), is inviting computer programmers, public health advocates, clinical researchers, entrepreneurs and innovators from all disciplines to
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy
- Details
- Category: FDA
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.
FDA updates warnings for fluoroquinolone antibiotics
- Details
- Category: FDA
The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.
FDA approves new medication for dry eye disease
- Details
- Category: FDA
The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyte function-associated antigen 1 (LFA-1) antagonist, approved by the FDA for dry eye disease.
More Pharma News ...
- FDA advances Precision Medicine Initiative by issuing draft guidances on next generation sequencing-based tests
- FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX
- FDA approves first buprenorphine implant for treatment of opioid dependence
- FDA approves new treatment for inhalation anthrax
- Launch of PRIME - Paving the way for promising medicines for patients
- FDA takes additional action to better understand safety of Essure, inform patients of potential risks
- FDA providing $2 million in new grants for natural history studies in rare diseases